Our pre-clinical work further builds upon these observations to characterize the activity of the BMS-911543 Jak2 inhibitor in a novel and highly aggressive murine model of spontaneously arising pancreatic cancer. This evidence concerns the gene JAK2 and pancreatic neoplasm.